All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub was pleased to speak to Mohamad Mohty, Hôpital Saint-Antoine, Paris, FR. We asked, When would you use ATG vs PTCy for GvHD prophylaxis?
When would you use ATG vs PTCy for GvHD prophylaxis?
In this video, Mohty discusses the use of PTCy post stem cell infusion for GvHD prophylaxis and refers to data published in 2019 in the EBMT registry that shows PTCy as potentially more effective than ATG for GvHD prophylaxis for mismatched, unrelated transplants. Mohty comments on the promising preliminary data that suggests ATG and PTCy could be combined in patients with a matched donor.
Update from the Heracles trial and expanded access program of MaaT013 in patients with SR aGvHD
During the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition and the 47th Annual Meeting of the European Society for Blood and Marrow...
Novel prophylactic therapies available before and after transplantation to reduce the risk of GvHD
This interview with Ali Bazarbachi, American University of Beirut, Beirut, LB, was on the topic of novel prophylactic therapies available before and...
Subscribe to get the best content related to GvHD delivered to your inbox